PhRMA guidelines for DTC on deck
Executive Summary
Pharmaceutical Research and Manufacturers of America is expected to release its revised guidelines for direct-to-consumer ads in early 2009, Hugh O'Neill, Sanofi-Aventis' head of market access and business development, reported at a conference on DTC Oct. 29. He indicated the code will include some type of moratorium on ads (1"The Pink Sheet," July 21, 2008, p. 27). Good news for PhRMA: Billy Tauzin, the trade group's president, "expects to be back on the job in the very near future," according to Senior VP Ken Johnson. Tauzin is on medical leave, but the association is "in daily contact with Billy as we begin to make plans for next year," Johnson says. "The great news is that he remains cancer-free and expects to remain at the helm of PhRMA for many years to come." Tauzin often uses a personal account of his battle with cancer, and the role of pharmaceuticals in his recovery, as part of his advocacy for the industry (2"The Pink Sheet," March 28, 2005, p. 31)
You may also be interested in...
“The New PhRMA:” Education, Communication Are Cornerstones, Tauzin Says
The Pharmaceutical Research & Manufacturers of America will become a resource to support communications efforts by member companies as part of an expanded mission, PhRMA CEO Billy Tauzin told the trade association March 18 in Washington, D.C
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.